Indacaterol/Glycopyrronium/Mometasone: A Review in Asthma
Funding The preparation of this review was not supported by any external funding.
Authorship and Conflict of interest Hannah Blair is a salaried employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.
Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability Not applicable.
information about this Adis Drug Review can be found here.
Abstract Indacaterol/glycopyrronium/mometasone (Enerzair® Breezhaler®) is a fixed-dose combination
of the long-acting β2 agonist (LABA) indacaterol, the long-acting muscarinic antagonist (LAMA) glycopyrronium and the inhaled corticosteroid (ICS) mometasone furoate (hereafter
referred to as mometasone) delivered via a capsule-based dry-powder inhaler. It is approved in the EU for use as maintenance treatment in adult
patients with inadequately controlled asthma who had experienced one or more
exacerbations in the previous year. The approval also includes an optional digital companion (sensor and app) that provides
data on the patient’s use of the inhaler. In the
52-week IRIDIUM trial in patients with inadequately controlled asthma, indacaterol/glycopyrronium/mometasone improved lung function to a
greater extent than LABA/ICS combinations (i.e. indacaterol/mometasone and
fluticasone propionate/salmeterol), but superiority in Asthma Control
Questionnaire 7 score was not shown. In the 24-week ARGON trial,
indacaterol/glycopyrronium/mometasone via a single inhaler was non-inferior to
fluticasone propionate/salmeterol + tiotropium via two inhalers with regard to
Asthma Quality of Life Questionnaire score. Indacaterol/glycopyrronium/mometasone
was generally well tolerated, and the most common adverse events were
respiratory in nature. In conclusion, combination therapy with
indacaterol/glycopyrronium/mometasone represents a valuable option for the
maintenance treatment of asthma, with the convenience of once-daily
administration via a single inhaler.
© Springer Nature Switzerland AG 2021